This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with
relapsed or refractory lymphoid malignancies. This study consists of two parts. The dose
exploration in part 1, studies cohorts of 3 subjects with relapsed or refractory lymphoid
malignancies and uses a practical continuous reassessment model [CRM] to guide dose
escalation and to define the MTD. The dose expansion in part 2 will enroll 20 subjects with
CLL at a dose no higher than the MTD and further explore the safety, PK, and clinical
activity of AMG 319 in this patient population.